Erick Gamelin

CIK: 0001950551

Transaction Breakdown

Open Market Buys (P)0 (0.0%)

High conviction signal

Open Market Sales (S)1 (8.3%)

Position reduction

Option Exercises (M)0 (0.0%)

Derivative conversions

Awards (A)4 (33.3%)

Compensation grants

Other (G, F, J, C, D, …)7 (58.3%)

Gifts, tax withholding, conversions, dispositions to the issuer and other codes

Companies & Roles (1)

ACRV

Acrivon Therapeutics, Inc.

Officer

Discretionary Trading P&L

Holdings

Transaction History (12 total)

ACRV
Acrivon Therapeutics, Inc.
Aug 18, 2026
Sale(S)
Direct
400 shares at avg. $2.01$804
ACRV
Acrivon Therapeutics, Inc.
May 18, 2026
Award(A)
Direct
38.6K shares-
ACRV
Acrivon Therapeutics, Inc.
May 14, 2026
Tax Payment(F)
Direct
404 shares at avg. $1.92$775.68
ACRV
Acrivon Therapeutics, Inc.
Mar 1, 2026
Award(A)
Stock Option (Right to Buy)
Direct
94.9K shares-
ACRV
Acrivon Therapeutics, Inc.
Feb 14, 2026
Tax Payment(F)
Direct
471 shares at avg. $1.63$767.73
ACRV
Acrivon Therapeutics, Inc.
Nov 14, 2025
Tax Payment(F)
Direct
403 shares at avg. $2.24$902.72
ACRV
Acrivon Therapeutics, Inc.
Aug 14, 2025
Tax Payment(F)
Direct
403 shares at avg. $1.39$560.17
ACRV
Acrivon Therapeutics, Inc.
May 14, 2025
Tax Payment(F)
Direct
403 shares at avg. $1.14$459.42
ACRV
Acrivon Therapeutics, Inc.
Mar 1, 2025
Award(A)
Stock Option (Right to Buy)
Direct
78.1K shares-
ACRV
Acrivon Therapeutics, Inc.
Feb 14, 2025
Tax Payment(F)
Direct
469 shares at avg. $5.42$3K
ACRV
Acrivon Therapeutics, Inc.
Nov 14, 2024
Tax Payment(F)
Direct
402 shares at avg. $7.92$3K
ACRV
Acrivon Therapeutics, Inc.
Mar 1, 2024
Award(A)
Stock Option (Right to Buy)
Direct
45K shares-

		Type	Shares	Price		Ownership
Aug 18, 2026	ACRV Acrivon Therapeutics, Inc.	Sale(S)	400	$2.01	$804	Direct
May 18, 2026	ACRV Acrivon Therapeutics, Inc.	Award(A)	38,584	-	$0	Direct
May 14, 2026	ACRV Acrivon Therapeutics, Inc.	Tax Payment(F)	404	$1.92	$776	Direct
Mar 1, 2026	ACRV Acrivon Therapeutics, Inc.	Award(A) Stock Option (Right to Buy)	94,946	-	-	Direct
Feb 14, 2026	ACRV Acrivon Therapeutics, Inc.	Tax Payment(F)	471	$1.63	$768	Direct
Nov 14, 2025	ACRV Acrivon Therapeutics, Inc.	Tax Payment(F)	403	$2.24	$903	Direct
Aug 14, 2025	ACRV Acrivon Therapeutics, Inc.	Tax Payment(F)	403	$1.39	$560	Direct
May 14, 2025	ACRV Acrivon Therapeutics, Inc.	Tax Payment(F)	403	$1.14	$459	Direct
Mar 1, 2025	ACRV Acrivon Therapeutics, Inc.	Award(A) Stock Option (Right to Buy)	78,078	-	-	Direct
Feb 14, 2025	ACRV Acrivon Therapeutics, Inc.	Tax Payment(F)	469	$5.42	$2,542	Direct
Nov 14, 2024	ACRV Acrivon Therapeutics, Inc.	Tax Payment(F)	402	$7.92	$3,184	Direct
Mar 1, 2024	ACRV Acrivon Therapeutics, Inc.	Award(A) Stock Option (Right to Buy)	45,045	-	-	Direct

1-12 of 12 transactions

About Gamelin Erick

Gamelin Erick (SEC CIK 0001950551) files insider reports with the SEC as Chief Development Officer of Acrivon Therapeutics, Inc. (ACRV).

Signal8 holds 12 ownership filings by Gamelin Erick, all Form 4s, filed between Nov 18, 2024 and Aug 20, 2026. Those filings report 12 transactions, from Mar 1, 2024 to Aug 18, 2026. Signal8's Form 4 history starts in Sep 2024.

The business address on Gamelin Erick's filings is in WATERTOWN, MA.

Recent filings by Gamelin Erick

Aug 18, 2026: Open-market sale of ACRV shares (Form 4, code S).
May 18, 2026: Grant or award of ACRV shares (Form 4, code A).
May 14, 2026: Tax withholding of ACRV shares (Form 4, code F).
Mar 1, 2026: Grant or award of ACRV derivative securities (Form 4, code A).
Feb 14, 2026: Tax withholding of ACRV shares (Form 4, code F).

Other insiders filing for Acrivon Therapeutics, Inc. (ACRV)

Miller Mary, Chief Legal Officer
Levin Michaela, Chief Business Officer
Blume-Jensen Peter, President and CEO
Peterson Katharine, Chief Accounting Officer
Devroe Eric, Chief Operating Officer
Levy Adam D., Chief Financial Officer

How to read Form 4 transaction codes